All Blogs / Industries / Medical / Pharmaceutical / New


Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars

The Centers for Medicare & Medicaid Services (CMS) has just released the Average Sales Prices (ASP) reimbursement data for the fourth quarter of 2017. You can download the drug pricing files here. Below, I use these data to explore the reimbursement and payer dynamics behind the relatively slow adoption of Inflectra, the first biosimilar of Remicade. Show More Summary

CBI’s Gross-to-Net Summit

CBI’s Gross-to-Net SummitNovember 15-16, 2017 | Philadelphia, PAwww.cbinet.com/GTNWith the total value of off-invoice discounts and rebates increasing over the last few years, it is pivotal that pharmaceutical and biotech manufacturers stay on the forefront of gross-to-net management. Show More Summary

Weekly Roundup 9.15.17

One season winds down, another offers hints of a beginning. I am afraid that both the regular Weekly Roundup as well as regular postings have lately been interrupted by some domestic issues that came up for me as well as … Continue reading ?

What’s Behind the Slowdown in Specialty Pharmacy M&A Deals?

It looks like specialty pharmacy merger & acquisition (M&A) activity has slowed down. In 2017 so far, only seven deals involving specialty pharmacies and infusion services companies have been announced. Each is listed below, along with...Show More Summary

Why Manufacturers and PBMs Should Worry About the Growth of Hospital-Owned Specialty Pharmacies

The American Society of Hospital Pharmacists (ASHP) has just released its latest national survey of pharmacy practice in hospital settings. (Free download) I always enjoy this annual treasure trove of insights. This year’s survey confirms the extent to which hospitals and health systems are pursuing specialty pharmacy dispensing revenues. Show More Summary

CBI’s 9th Federal Pricing and Reporting Summit – VA DoD PHS

CBI’s 9th Federal Pricing and Reporting Summit – VA DoD PHSNovember 16-17, 2017 | Philadelphia, PAwww.cbinet.com/fedpricingCBI is pleased to invite you to attend the Federal Pricing and Reporting Summit, being held November 16-17, 2017 in Philadelphia, PA. Show More Summary

2016’s Fastest-Growing, Private Specialty Pharmacies (From the Inc. 5000)

Time for our annual review of the latest Inc. 5000 list, the magazine’s annual ranking of the fastest-growing private companies in the United States. The list offers a valuable snapshot of the dynamic specialty pharmacy industry. This...Show More Summary

Life Sciences 2nd Annual Value-Based Contracting Summit

Life Sciences 2nd Annual Value-Based Contracting SummitOctober 23-24, 2017 | Alexandria, VAwww.worldcongress.com/valuebasedThe Life Sciences 2nd Annual Value-Based Contracting Summit brings together key stakeholders to examine risk sharing strategies to overcome operational challenges and execute successful value-based contracts. Show More Summary

Weekly Roundup – 9.1.17

As hurricane season made itself felt this week, summer seems over in the east. Kids are back to school and this weekend summer whites and linens have their final appearance before next Memorial Day. Meanwhile it was a very busy … Continue reading ?

The State of Specialty Pharmacy 2017: Reflections from #Asembia17 (rerun)

This week, I’m rerunning some popular posts while I work on the forthcoming 2017-18 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post and comments from May 2017. FYI, Asembia's...Show More Summary

A Reality Check on Amazon’s Pharmacy Ambitions (rerun)

This week, I’m rerunning some popular posts while I work on the forthcoming 2017-18 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post and comments from May 2017. CNBC reported last week that Amazon may enter the pharmacy and/or pharmacy benefit manager (PBM) market. Show More Summary

Which PBM Best Managed Drug Spending in 2016: CVS Health, Express Scripts, MedImpact, or Prime? (rerun)

This week, I’m rerunning some popular posts while I work on the forthcoming 2017-18 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post and comments from March 2017.  ICYMI, I...Show More Summary

Profits in the 2017 Fortune 500: Manufacturers vs. Wholesalers, PBMs, and Pharmacies (rerun)

This week, I’m rerunning some popular posts while I work on the forthcoming 2017-18 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Click here to see the original post and comments from June 2017.  ICYMI, IShow More Summary

4th Annual Rare Disease Market Access and Commercialization Summit

4th Annual Rare Disease Market Access and Commercialization SummitOctober 23-24, 2017 | Boston, MAwww.worldcongress.com/rarediseaseJoin your peers at the 4th Annual Rare Disease Market Access and Commercialization Summit for a deep examination...Show More Summary

Specialty Brand Sales Excel Today, But What About Tomorrow?

@QuintilesIMS teamed up with #PharmaForce to provide a framework for product launch assessment. The following is an excerpt. Download the entire report here.The chart below shows the total amount of revenue associated with launch brands in the year that they launch. Show More Summary

My Moment with Jay Thomas

A departure from the usual FDA fare. The blog is meant to cover FDA issues, but also various aspects of communications. This is a story about media training, sort of. Jay Thomas died yesterday. He was 69 years old. He … Continue reading ?

Drug Channels News Roundup, August 2017: Amazon, Express Scripts, Walgreens, PharMerica, Rebates, and Bezos Business Wisdom

The eclipse has passed! Now it’s time to enjoy this blinding collection of curious questions, filtered through the all-seeing Drug Channels viewfinder. What are Amazon’s actual prospects in the drug channel? What does Express Scripts...Show More Summary

CBI’s Gross-to-Net Summit

CBI’s Gross-to-Net SummitNovember 15-16, 2017 | Philadelphia, PAwww.cbinet.com/GTNA recent Drug Channels blog post focused on a QuintilesIMS report, discussing how the total value of pharmaceutical manufacturers’ off-invoice discounts,...Show More Summary

PhRMA May Be Shooting Itself in the Foot by Criticizing FDA DTC Studies

As reported by RAPS (here), the Pharmaceutical Research and Manufacturers of America (PhRMA) is "harshly criticizing the US Food and Drug Administration's (FDA) research focused on prescription drug advertising and promotion and calling...Show More Summary

Diplomat Sees Declining DIR Fee Impact—and Perhaps Readies a PBM Strategy

Last week, Diplomat Pharmacy released its quarterly earnings, which included new details about the financial impact of Direct and Indirect Remuneration (DIR) fees. I provide some background on DIR fees below. Diplomat, as a public company, is the only entity that is obligated to publish truthful information about DIR fees. Show More Summary

Copyright © 2015 Regator, LLC